Xencor, Inc. (NASDAQ:XNCR) Position Increased by Vanguard Group Inc.

Vanguard Group Inc. boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 1.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,767,249 shares of the biopharmaceutical company’s stock after purchasing an additional 115,886 shares during the period. Vanguard Group Inc. owned 11.07% of Xencor worth $143,669,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Xencor by 2.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,798 shares of the biopharmaceutical company’s stock valued at $654,000 after buying an additional 615 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,015 shares during the last quarter. CWM LLC raised its holdings in shares of Xencor by 498.7% during the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,147 shares in the last quarter. Signaturefd LLC lifted its stake in shares of Xencor by 367.7% in the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,151 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Xencor by 13.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,215 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 1,640 shares in the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on XNCR. Raymond James cut their target price on Xencor from $58.00 to $40.00 and set a “strong-buy” rating on the stock in a report on Friday, June 14th. Royal Bank of Canada decreased their target price on Xencor from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Friday, June 14th. BMO Capital Markets dropped their price target on shares of Xencor from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th. StockNews.com raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Finally, BTIG Research dropped their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, April 16th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.38.

Xencor Stock Up 1.9 %

Shares of XNCR opened at $18.61 on Friday. Xencor, Inc. has a 52 week low of $16.49 and a 52 week high of $26.84. The firm has a market capitalization of $1.15 billion, a P/E ratio of -8.50 and a beta of 0.69. The company has a 50-day simple moving average of $21.77 and a 200-day simple moving average of $21.43. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.28). The firm had revenue of $12.80 million during the quarter, compared to the consensus estimate of $23.07 million. Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. Xencor’s revenue was down 32.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.02) EPS. On average, equities research analysts expect that Xencor, Inc. will post -3.5 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.